Alphabetical listing of all products

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Prices
  • 5 mg - 194 EUR
  • 25 mg - 776 EUR
  • 100 mg - 2328 EUR

Bafetinib

Bafetinib is an orally available, dual BCR/Abl and Lyn kinase inhibitor that was developed to treat BCR/Abl positive leukemias such as chronic myelogenous leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia (AML). It is 25- to 55-fold more potent than imatinib in vitro and at least 10-fold more potent in vivo. Bafetinib inhibits 12 of the 13 most frequent imatinib-resistant Bcr-Abl isoforms originating from point mutations, but not that bearing the Thr315Ile mutation.

catalogue number: B096
synonyms: INNO-406, NS-187
CAS: 859212-16-1
MW: 576.62 g/mol

References
Blood. 2005 Dec 1;106(12):3948-54. PMID: 16105974
Curr Opin Investig Drugs. 2010 Dec;11(12):1450-65. PMID: 21154127